Affiliation:
1. Department of ‘A’, Children’s Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou 310052, China
Abstract
Coronavirus disease 2019 (COVID-19) is a worldwide public health and economic threat, and virus variation amplifies the difficulty in epidemic prevention and control. The structure of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been studied extensively and is now well defined. The S protein is the most distinguishing feature in terms of infection and immunity, mediating virus entrance and inducing neutralizing antibodies. The S protein and its essential components are also the most promising target to develop vaccines and antibody-based drugs. Therefore, the key site mutation in the S gene is of high interest. Among them, RBD, NTD, and furin cleavage sites are the most mutable regions with the most mutation sites and the most serious consequences for SARS-CoV-2 biological characteristics, including infectivity, pathogenicity, natural immunity, vaccine efficacy, and antibody therapeutics. We are also aware that this outbreak may not be the last. Therefore, in this narrative review, we summarized viral variation and prevalence condition, discussed specific amino acid replacement and associated immune challenges and attempted to sum up some prevention and control strategies by reviewing the literature on previously published research about SARS-CoV-2 variation to assist in clarifying the mutation pathway and consequences of SARS-CoV-2 for developing countermeasures against such viruses as soon as possible.
Funder
Fundamental Research Funds for the Central Universities
National Natural Science Foundation of China
Natural Science Foundation of Zhejiang Province
Subject
Pharmacology (medical),Infectious Diseases,Drug Discovery,Pharmacology,Immunology
Reference95 articles.
1. Liu, Y., and Ye, Q. (2022). Safety and Efficacy of the Common Vaccines against COVID-19. Vaccines, 10.
2. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine;Baden;N. Engl. J. Med.,2021
3. Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine;Polack;N. Engl. J. Med.,2020
4. Liu, Y., and Ye, Q. (2022). Nucleic Acid Vaccines against SARS-CoV-2. Vaccines, 10.
5. SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with COVID-19;Chen;N. Engl. J. Med.,2021
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献